Brain protein could be preventive measure against Alzheimer’s, new study suggests

As effective treatments for Alzheimer’s continue to elude the medical community, new research from Iowa State University has shed light onto a particular protein and how it can predict the likelihood of someone developing Alzheimer’s.

A study, published in the journal Brain, Behavior and Immunity, suggests that there is a link between brain activity and the presence of NPTX2, a brain protein essential for building memories. The researchers found that high levels of the protein correlate with better memory and more brain volume, while lower levels of the protein were associated with loss of memory and less volume.

In the study, authors Auriel Wilette, assistant professor of food science and human nutrition at Iowa State, and Ashley Swanson, graduate research assistant at Iowa State, analyzed data from the Alzheimer’s Disease Neuroimaging Initiative to find which aspects of the immune system were most relevant to tracking Alzheimer’s disease progression.

They found that participants with more years of education has higher levels of the protein, meaning that people who have complex jobs and are active mentally and socially could have less problems with memory loss.

Ultimately, the protein could be used as a way for physicians to predict the progression of memory loss and brain atrophy in Alzheimer’s patients. Now researchers are looking for methods to boost NPTX2 levels, which could be explored in future studies.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.